Dr. Manasi Shah

Meet our distinguished medical professional, Dr. Manasi Shah, an accomplished Hematologist and Medical Oncologist dedicated to improving lives through advanced medical practices and innovative research.

Dr. Manasi Shah's journey towards becoming a leading medical expert began with her M.B.B.S. degree from Smt. N.H.L. Municipal Medical College, Gujarat University, India, which she earned from August 1999 to April 2005. She then pursued a rigorous Internal Medicine Residency at Bridgeport Hospital, Yale School of Medicine, Connecticut, USA, from June 2006 to June 2009. Her pursuit of excellence continued with a Hematology/Oncology Fellowship at the University of Connecticut, Farmington, Connecticut, USA, from July 2009 to June 2012. To further enhance her skills, she completed a specialized Bone Marrow Transplantation training at Memorial Sloan Kettering, New York, USA, from March 2011 to May 2011.

Dr. Shah's clinical journey encompasses a wealth of experience and expertise:

• Clinical Assistant Professor at the Department of Medicine/Hematology-Oncology, University of Connecticut, Farmington, Connecticut (September 2012- December 2012).
• Attending Physician at Lawrence Medical Associates, NewYork-Presbyterian Medical Group Westchester, New York (June 2013-July 2015).
• Current role as a Consultant, Medical Oncologist, and Hematologist at the prestigious HCG Cancer Center, Ahmedabad (since September 2015).

Dr. Shah is recognized for her outstanding achievements and holds the following American Board certifications:

• Board certified in Internal Medicine (2009).
• Board certified in Hematology (2012).
• Board certified in Medical Oncology (2012).

Dr. Shah's impact extends beyond the clinic, with active involvement in groundbreaking research and clinical trials.

Clinical Trial Experience – Principal investigator in the following national and international trials (2017-2023)
An open-label, multicentre, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease CLEE011A2404.

A multicentric, open label, single arm study to evaluate the safety and efficacy of INTP26 (trastuzumab biosimilar) in patients with HER2-overexpressing breast (early or metastatic) cancer or metastatic gastric cancer.

A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrazole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

A Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)

A Phase III, randomized, open label, multicenter study evaluating efficacy and safety of adjuvant girdestrant compared with physicians choice of adjuvant endocrine therapy in patients with ER positive, Her2 neu negative, early breast cancer (Lidera)

Treatment patterns and clinical outcomes among Indian patients receiving Palbociclib combinations for HR+/HER2- Advanced/Metastatic breast cancer in real world setting.

A randomized multicentric, open label, study to evaluate the safety and efficacy of trastuzumab emtansine (TDM1) (Zydus vs. Roche) in patients with HER2-overexpressing metastatic breast cancer beyond 1st line.

Awarded in 2011 by the Connecticut Health Breast Initiative for the research project "Impact of HER2 on the outcomes of patients with small breast cancers"

Shah M, Agarwal B, Recent advances in management of acute myeloid leukemia (AML), Indian J Pediatr. 2008 Aug;75(8):831-7.

Saif MW, Shah M., K-ras mutations in colorectal cancer: a practice changing discovery, Clin Adv Hematol Oncol. 2009 Jan;7(1):45-64.

Saif MW, Shah M, Shah A, Fluoropyrimidine associated cardiotoxicity: revisited, Expert Opinion in Drug Safety, 2009 March: 8 (2): 191-202.

Shah M, Summerhill E, Manthous CA, Medical Professionalism in the New Millennium: Are there intercultural differences?, Conn Med. 2009 May;73(5):289-94.

Shah M, Saif MW, Pancreatic Cancer and Thrombosis: Highlights from the “2010 ASCO Annual Meeting”. J Pancreas (Online) 2010 Jul YY; 11(4):331-333

Shah M, Hotchkiss S, Shanley J, Davies M., Ferencz T.M., Syrigos K, Saif M, Successful desensitization with cetuximab (CET) after hypersensitivity reaction (HSR) to panitumumab (PAN) and CET in patients (pts) with metastatic colorectal cancer (mCRC), J Clin Oncol 26: 2008 (May 20 suppl; abstr 15092)

Shah M, Shah A, Raloxifene and Venous Thromboembolism: A Systematic Review of Randomized Clinical Trials, J Oncol Pharm Practice 14 (2), 2008: 82

Shah M, Bortezomib associated pulmonary toxicity, J Oncol Pharm Practice 14 (2), 2008: 98

Shah M, Shah A, Effects of Iron Therapy on Congestive Heart Failure Patients – A Meta-Analysis, Haematologica 2008; 93(s1): 387

Lindner R, Offor O, Chaves J, Fischbach N, Shah M, Activation of the Insulin-Like Growth Factor Pathway distinguishes African American from European American patients with triple-negative breast cancer by Gene Expression Profiling, Annual San Antonio Breast cancer Symposium, December 2009

Shah M, Fischbach N, Outcomes of triple negative breast cancer in African- Americans vs. Caucasians: a community based study, Annual San Antonio Breast Cancer Symposium, December 2008.

Shah M, Shah A, Systematic review of randomized clinical trials: Does pegylated liposomal doxorubicin improve response rate in HIV-associated Kaposis’s sarcoma?, Canadian Association of Medical Oncologists May 2008.

Shah M, Abdelsayeed G, Does age affect variations in anatomic sub-site location of colon cancer patients? Canadian Association of Medical Oncologists, May 2008.

Shah M, Abdelsayeed G,Ethnic Variations in the outcomes of Colon Cancer – A Single Center Experience, Canadian Association of Medical Oncologists, May 2008.

Shah M, Kanuga J, Anaphylactic Reaction due to Exenatide: A Case Report, American College of Allergy, Asthma and Immunology, November, 2007.

Shah M., Gregorian A, Adjepong Y, Manthous CA; Intercultural Comparisons of Medical Professionalism, American College of Physicians CT Regional Meeting, October 2007.

Dr. Shah is an esteemed member of several prestigious professional societies:

1. Indian Society of Pediatric and Medical Oncology (ISMPO).
2. European Society of Medical Oncology.
3. American Society of Clinical Oncology.
4. Association of Gynec Oncologists of India.

At Amba Health Centre & Hospital, Dr. Manasi Shah stands as a beacon of medical excellence, dedicating her life to delivering the highest standard of care to patients while pushing the boundaries of medical science through her pioneering research and unwavering commitment to advancement.

Experience world-class medical care and expertise with Dr. Manasi Shah at Amba Health Centre & Hospital. Your journey to better health starts here.